NASDAQ:OCGN - Ocugen Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.90
  • Forecasted Upside: 37.15 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.76
▼ -0.55 (-8.72%)

This chart shows the closing price for OCGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ocugen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCGN

Analyst Price Target is $7.90
▲ +37.15% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ocugen in the last 3 months. The average price target is $7.90, with a high forecast of $15.00 and a low forecast of $4.00. The average price target represents a 37.15% upside from the last price of $5.76.

This chart shows the closing price for OCGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Ocugen. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2021Noble FinancialReiterated RatingBuy$15.00Low
11/2/2021Roth CapitalReiterated RatingHold$6.00High
11/2/2021Cantor FitzgeraldReiterated RatingNeutral$4.00High
10/28/2021Noble FinancialReiterated RatingBuy$15.00Low
8/9/2021HC WainwrightReiterated RatingBuy$10.00Low
7/26/2021Noble FinancialInitiated CoverageBuy$6.80Medium
6/11/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $10.00High
6/10/2021Roth CapitalDowngradeBuy ➝ Neutral$10.00 ➝ $6.00High
6/10/2021Chardan CapitalLower Price TargetNeutral$8.00 ➝ $4.50N/A
5/13/2021Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$15.00 ➝ $11.00N/A
5/10/2021Chardan CapitalLower Price TargetNeutral$13.00 ➝ $8.00High
5/7/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$11.00High
3/4/2021Roth CapitalBoost Price TargetBuy$9.00 ➝ $10.00Medium
2/9/2021Chardan CapitalDowngradeBuy ➝ NeutralLow
2/4/2021HC WainwrightUpgradeNeutral ➝ Buy$4.50Low
2/3/2021Roth CapitalBoost Price TargetPositive ➝ Buy$1.00 ➝ $8.00High
2/3/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$1.00 ➝ $4.00Medium
11/16/2020Roth CapitalInitiated CoverageBuy$1.00Low
11/9/2020HC WainwrightReiterated RatingHoldHigh
10/9/2020Cantor FitzgeraldInitiated CoverageOverweight$1.00High
8/17/2020HC WainwrightReiterated RatingHoldHigh
8/16/2020Chardan CapitalReiterated RatingBuy$0.70High
6/3/2020Chardan CapitalLower Price TargetBuy$2.00 ➝ $0.70Medium
6/1/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
5/17/2020Chardan CapitalReiterated RatingBuy$2.00Low
3/30/2020Chardan CapitalReiterated RatingBuy$2.00High
12/20/2019HC WainwrightInitiated CoverageBuy$1.25High
11/27/2019Chardan CapitalInitiated CoverageBuy$2.00High
(Data available from 12/5/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2021
  • 6 very positive mentions
  • 41 positive mentions
  • 14 negative mentions
  • 1 very negative mentions
7/8/2021
  • 18 very positive mentions
  • 38 positive mentions
  • 14 negative mentions
  • 3 very negative mentions
8/7/2021
  • 13 very positive mentions
  • 29 positive mentions
  • 12 negative mentions
  • 4 very negative mentions
9/6/2021
  • 4 very positive mentions
  • 28 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/6/2021
  • 8 very positive mentions
  • 29 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
11/5/2021
  • 16 very positive mentions
  • 40 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
12/5/2021

Current Sentiment

  • 16 very positive mentions
  • 40 positive mentions
  • 7 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Ocugen logo
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Read More

Today's Range

Now: $5.76
Low: $5.65
High: $6.40

50 Day Range

MA: $8.41
Low: $5.76
High: $15.67

52 Week Range

Now: $5.76
Low: $0.28
High: $18.77

Volume

16,970,472 shs

Average Volume

46,767,520 shs

Market Capitalization

$1.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocugen?

The following Wall Street analysts have issued research reports on Ocugen in the last twelve months: Cantor Fitzgerald, Chardan Capital, HC Wainwright, Noble Financial, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for OCGN.

What is the current price target for Ocugen?

5 Wall Street analysts have set twelve-month price targets for Ocugen in the last year. Their average twelve-month price target is $7.90, suggesting a possible upside of 37.2%. Noble Financial has the highest price target set, predicting OCGN will reach $15.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $4.00 for Ocugen in the next year.
View the latest price targets for OCGN.

What is the current consensus analyst rating for Ocugen?

Ocugen currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OCGN, but not buy more shares or sell existing shares.
View the latest ratings for OCGN.

How do I contact Ocugen's investor relations team?

Ocugen's physical mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company's listed phone number is (484) 328-4701 and its investor relations email address is [email protected] The official website for Ocugen is ocugen.com.